Navigation Links
Newly Published Study Results Showed That Two Mealtime Insulin Dosing Algorithms Were Effective for Patients with Type 2 Diabetes
Date:7/22/2008

to help manage the potential risks that come with prolonged hyperglycemia," said Dr. Bergenstal. "The Adjust to Target trial demonstrated that basal-bolus insulin therapy may be an effective option for the many people with type 2 diabetes who are not achieving glycemic targets with their current insulin regimen."

About the Trial

Study participants were 28-71 years old, had type 2 diabetes for greater than or equal to 6 months and mean +/- SD A1C values of 8.1 +/- 0.9% (Simplified Algorithm) and 8.3 +/- 0.9% (Carb Counting Algorithm) at screening. They had taken greater than or equal to 2 insulin injections/day (36 percent on 2 injections, 64 percent on more than 2 injections) +/- metformin (one-third were on metformin), for greater than or equal to 3 months before study entry. Upon entry into the study, 37 percent were using Lantus(R) and at least one injection of a rapid-acting insulin analog, 36 percent were using a pre-mixed insulin and the remainder were on a combination of various other diabetes treatment regimens.

About Diabetes

Diabetes is a chronic, widespread condition in which the body does not produce or properly use insulin -- the hormone needed to transport glucose (sugar) from the blood into the cells of the body for energy. More than 230 million people worldwide are living with the disease and this number is expected to rise to a staggering 350 million within 20 years. It is estimated more than 20 million Americans have diabetes, including an estimated 6.2 million who remain undiagnosed.

At the same time, more than 40 percent of those diagnosed are not achieving the blood sugar control target of A1C <7 percent recommended by the American Diabetes Association (ADA). The A1C test measures average blood glucose levels over a two- to three-month period.

About sanofi-aventis

Sanofi-aventis, a leading global pharmaceutical company, discovers, develops and distributes therapeutic solutions to improve the live
'/>"/>

SOURCE sanofi-aventis
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
2. Sixty-One Percent of Newly Diagnosed Parkinsons Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis
3. Phase III Clinical Trial in Newly Diagnosed Multiple Myeloma Stopped Early Due to Highly Significant Efficacy Advantage of VELCADE(R) (Bortezomib) for Injection Based Therapy Across All Endpoints
4. Newly Published Phase II Study Shows the Investigational Drug Vandetanib Prolongs Progression-Free Survival in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
5. New Data to Support VELCADE(R) (Bortezomib) For Injection Based Therapies as Setting New Standards in The Care of Newly Diagnosed Patients With Multiple Myeloma
6. Newly Approved HIV Drug Shows Great Promise
7. New Data Support High Complete Remission Rates With VELCADE(R) (Bortezomib) for Injection Based Therapies in Patients With Newly Diagnosed Multiple Myeloma
8. VELCADE(R) (Bortezomib) for Injection Based Treatment Delivers Impressive Complete Response and Survival in Patients With Newly Diagnosed Multiple Myeloma
9. Multiple Clinical Trials of VELCADE(R) (Bortezomib) for Injection Based Therapies Demonstrate High Complete Remission Rates in Patients with Newly Diagnosed Multiple Myeloma
10. Newly Published Study Shows OPKOs siRNA Bevasiranib Is Taken Up by Target Tissues in the Eye
11. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... , Sept. 19, 2014  BioSpecifics Technologies Corp. (NASDAQ: ... class collagenase-based products marketed as XIAFLEX ® in the ... that BioSpecifics, President, Tom Wegman , will present a ... in the Biotech Industry Conference. The presentation ... p.m. EDT at the Millennium Broadway Hotel in ...
(Date:9/19/2014)... , Sept. 19, 2014  Over 200 runners ... Future to Benefit the Radiation Oncology Institute (ROI), hosted ... at Golden Gate Park in San Francisco.  ... Moore , CEO of Radiation Business Solutions, "but ... have raised over $70,000 for the ROI this year. ...
(Date:9/19/2014)... Mass. , Sept. 19, 2014   Personal ... advanced cancer genome analysis and testing services, and ... and developing highly selective kinase inhibitors for genomically ... study of malignant mixed Mullerian tumors (MMMT), an ... system, also known as carcinosarcoma. The new ...
Breaking Medicine Technology:BioSpecifics Technologies Corp. to Present at the 21st Annual BioCentury NewsMakers in the Biotech Industry Conference 2Fifth Annual 5K Run for the Future to Benefit the Radiation Oncology Institute Breaks Attendance, Donation Records 2Fifth Annual 5K Run for the Future to Benefit the Radiation Oncology Institute Breaks Attendance, Donation Records 3First Discovery Of Actionable Genetic Alterations In A Deadly Cancer Reported By Personal Genome Diagnostics And Blueprint Medicines 2First Discovery Of Actionable Genetic Alterations In A Deadly Cancer Reported By Personal Genome Diagnostics And Blueprint Medicines 3First Discovery Of Actionable Genetic Alterations In A Deadly Cancer Reported By Personal Genome Diagnostics And Blueprint Medicines 4
(Date:9/21/2014)... Burnaby Physiotherapists at Absolute PhysioCare & Sports ... to help them with preventative care. This is part ... will help clients understand their problem in a better ... in the healing process. With higher knowledge of their ... to facilitate the therapy that is initiated by the ...
(Date:9/21/2014)... 21, 2014 "I wanted to be ... to consume sugary, foul-tasting energy drinks," said an inventor ... just want to drink plain, old coffee. That is ... , He developed ENERG CHEWING GUM to provide a ... loss. The formula contains nutritious vitamins, minerals and antioxidants. ...
(Date:9/21/2014)... New York, New York (PRWEB) September 21, 2014 ... http://www.risperdallawsuitcenter.com/ ) continue to move forward in Pennsylvania’s ... reports. According to court documents, the proceeding’s next ... 2014. (Risperdal Litigation, case number 100300296) , “Our ... have filed Risperdal lawsuits in this litigation. We ...
(Date:9/21/2014)... Originally approved by the Food ... (fluticasone propionate) is a synthetic ICS therapy with ... maintenance treatment of asthma prophylactically in children and ... Diskus and HFA, which received the FDA approval ... fluticasone propionate, can bind to glucocorticoid receptors with ...
(Date:9/21/2014)... (PRWEB) September 21, 2014 An experienced ... released its newest hosting ranking list and announced that ... best VPS hosting suppliers. , There has been ... new demand has resulted in an increase in the ... of different services at very affordable prices. VPS (Virtual ...
Breaking Medicine News(10 mins):Health News:Burnaby Physiotherapists Now Provide Educational Information for Preventative Care 2Health News:Risperdal Lawsuits Move Forward in Pennsylvania Litigation, As Court Schedules October Meeting, Bernstein Liebhard LLP Reports 2Health News:Risperdal Lawsuits Move Forward in Pennsylvania Litigation, As Court Schedules October Meeting, Bernstein Liebhard LLP Reports 3Health News:Risperdal Lawsuits Move Forward in Pennsylvania Litigation, As Court Schedules October Meeting, Bernstein Liebhard LLP Reports 4Health News:Flovent Asthma Market Sales & SWOT Analysis and Forecasts to 2023 in New Report Available at LifeScienceIndustryResearch.com 2Health News:Flovent Asthma Market Sales & SWOT Analysis and Forecasts to 2023 in New Report Available at LifeScienceIndustryResearch.com 3Health News:Flovent Asthma Market Sales & SWOT Analysis and Forecasts to 2023 in New Report Available at LifeScienceIndustryResearch.com 4Health News:Top10BestSEOHosting.com: FatCow, GoDaddy And Bluehost Are The Best VPS Hosting Suppliers 2
... Menveo not available in US yet, British researchers note , , ... meningitis vaccine appears to offer protection for babies against several ... and Canadian researchers report. , The new vaccine, which is ... four strains of meningococcal disease in all age groups, according ...
... a stage, then proteins would rank among the lead ... These large biological molecules hold many starring roles, and ... genes. They are production powerhouses, regulating the basic processes ... that produce or use energy. Others regulate genes. , ...
... enjoy things less. Such satiation causes our favorites to lose ... pushes us to escalate our spending on novelty. Life has ... better and better experiences just to stay happy. However, new ... Research finds that paying attention to details can help us ...
... and Queens Groups Will Work to Prevent Sudden Cardiac,Arrest, ... 8 The Sudden Cardiac Arrest,Association (SCAA) announced today ... it builds a network of local organizations to help ... The Queens chapter is led by Lorraine Monaghan, ...
... Work to Prevent Sudden Cardiac Arrest, Through Public ... Sudden Cardiac Arrest,Association (SCAA) announced today that it has ... of local organizations to help carry out,its mission of ... chapter is led by Connie Snell of Austin who ...
... WASHINGTON, Jan. 8 The Department of Labor,s,Occupational ... comment period for the review of its methylene ... was originally announced in,the July 10, 2007, Federal ... issued the Standard in 1997 to protect employees ...
Cached Medicine News:Health News:New Meningitis Vaccine Works in Infants 2Health News:New Meningitis Vaccine Works in Infants 3Health News:Protein power: Researchers trigger insulin production in diabetic mice 2Health News:Protein power: Researchers trigger insulin production in diabetic mice 3Health News:Trying to stay on a strict diet? Focus on the details 2Health News:Sudden Cardiac Arrest Association Launches Long Island and Queens Chapters 2Health News:Sudden Cardiac Arrest Association Launches Long Island and Queens Chapters 3Health News:Sudden Cardiac Arrest Association Launches Austin and Lubbock Chapters 2Health News:Sudden Cardiac Arrest Association Launches Austin and Lubbock Chapters 3Health News:OSHA Extends Comment Period for Lookback Review of Methylene Chloride Standard 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: